BrainsWay Ltd. reports developments in noninvasive neurostimulation treatments for mental health disorders. The company markets its proprietary Deep TMS platform, with FDA-cleared indications that include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and derives revenue from leases and sales of Deep TMS systems.
Recurring updates include financial results, operating guidance, system placements, reimbursement and payer coverage for TMS therapy, clinical data for Deep TMS protocols such as SWIFT, and additional regulatory clearances. Company news also covers strategic minority-stake and milestone-based investments in mental health providers and related neurostimulation technologies, along with investor conference participation and operational updates across its U.S. and Israel-based business.
BURLINGTON, Mass. and JERUSALEM, Nov. 30, 2021 – BrainsWay (NASDAQ: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, announced that CEO Christopher von Jako, Ph.D., will present at the Sidoti December Micro-Cap Investor Conference on December 9, 2021, at 10 am EST. The event, occurring December 8-9, will also feature one-on-one investor meetings. BrainsWay's Deep TMS technology is FDA-cleared for major depressive disorder, OCD, and smoking addiction. For more details, visit www.brainsway.com.
BrainsWay Ltd. (BWAY) reported a 34% revenue growth year-over-year, reaching $8.1 million for Q3 2021, driven by high demand for its Deep TMS therapy. The company achieved a total revenue of $21.2 million for the first nine months, marking a 41% increase compared to the same period in 2020. The installed base of Deep TMS systems rose by 22% to 717 units. Regulatory clearance was obtained for Deep TMS therapy for treating anxious depression, adding to its portfolio. Despite a net loss of $1.8 million in Q3, cash reserves increased to $55.3 million.
BrainsWay Ltd. (NASDAQ: BWAY), a leader in noninvasive neurostimulation for mental health, will report its Q3 2021 financial results on November 17, 2021, before U.S. market opening. The company plans to host a conference call at 8:30 AM ET to discuss the results and update on operations. BrainsWay is recognized for its Deep TMS™ technology, which is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The call will be available for replay for 30 days.
BrainsWay Ltd. (NASDAQ: BWAY) has appointed Dr. Zafiris Daskalakis to its scientific advisory board, enhancing its expertise in brain stimulation. Dr. Daskalakis, Chair of Psychiatry at UCSD, brings extensive research knowledge and over 450 publications in neurophysiology and psychiatric disorders. This strategic addition aims to strengthen BrainsWay’s growth and clinical impact as it seeks to expand the application of its Deep TMS™ technology for mental health treatment. CEO Christopher von Jako emphasized the importance of Dr. Daskalakis’s insights in navigating the company's future.
BrainsWay Ltd. (NASDAQ: BWAY) has released promising data from a pivotal clinical trial published in World Psychiatry, supporting its Deep TMS™ treatment for smoking addiction. Conducted across 12 U.S. and 2 Israeli sites with 262 chronic smokers, the trial showed over 25% of patients achieving a minimum of 4 weeks of abstinence. The treatment, which is FDA-cleared, demonstrated significant reductions in smoking behavior. BrainsWay is engaged in a controlled market release to refine its business model and gather post-marketing data.
BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 – BrainsWay (NASDAQ: BWAY) announced that CEO Christopher von Jako will present at two investment conferences in September. The first is the Oppenheimer & Co. Fall Healthcare Life Sciences & Medtech Virtual Summit from September 20-23, with a presentation on September 22 at 3:45 PM ET. The second is the Cantor Fitzgerald Global Healthcare Conference from September 27-30, with a presentation on September 27 at 3:20 PM ET. Investors can arrange meetings with management during these events.
BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 – BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation for mental health, will have its CEO, Christopher von Jako, present and hold investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The company is recognized for its Deep TMS™ technology, with three FDA-clearances for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. With ongoing clinical trials, BrainsWay aims to expand global access to its innovative treatments.
BrainsWay Ltd. announced on August 18, 2021, that it received 510(k) clearance from the FDA for its Deep Transcranial Magnetic Stimulation (Deep TMS™) System. This allows BrainsWay to market its system for reducing anxiety symptoms in adults with depression, enhancing its existing depression indication. The company presented data from 573 patients across 11 studies, showing clinically meaningful treatment effects. This clearance broadens its reach in the mental health market, potentially impacting millions suffering from anxious depression, as 60-90% of depressed patients exhibit anxiety symptoms.
BrainsWay Ltd. reported a strong Q2 2021 performance, achieving total revenues of $7.0 million, a 45% increase year-over-year. The installed base of Deep TMS™ systems rose to 682, marking a 20% growth. The company is gaining traction in OCD reimbursement, with key coverage policies from Centene and HCSC impacting 42 million covered lives. Operating loss was $1.5 million, up from $215 thousand in Q2 2020, while cash reserves increased to $55.9 million.
BrainsWay Ltd. (NASDAQ: BWAY) announced it will report its second quarter 2021 financial results and operational highlights on August 11, 2021, before U.S. markets open. A conference call will follow at 8:30 AM ET to discuss these results and business updates. BrainsWay is recognized for its advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep TMS™ technology. The company has achieved FDA clearance for three indications, including major depressive disorder, and continues expanding clinical trials for additional disorders.